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A b s t r a c t  
The present investigation was aimed with the objective of developing fast dissolving oral films of 
Eletriptan HBr in order to attain quick onset of action for the better management of migraine attack. 
Twenty five formulations were prepared by solvent casting method using different polymer types, 
plasticizer types, surfactant concentrations and different ratio of hydroxypropyl methyl cellulose and 
maltodextrin. The prepared films were evaluated for folding endurance, thickness, drug content, in 
vitro/in vivo disintegration time, drug release and tensile test. The optimized formulation F17 
containing HPMC 15cp and maltodextrin showed minimum in vitro disintegration time 11 seconds, 
highest dissolution rate i.e. 98.5% of drug within 10 min. The optimized film was further evaluated for 
bioavailability compared with a marketed product (Relpax-20mg). The pharmacokinetic results 
revealed that the fast dissolving oral films has higher peak blood concentration (Cmax, 
0.455μ0.1øg/ml) within shorter time (Tmax, 0.5 hours), indicating rapid absorption and faster onset of 
action with acceptable bioavailability value. Therefore, the oral fast dissolving film is considered to 
be potentially useful for the treatment of migraine disease where quick onset of action is desired, 
also improved patient compliance. 
Keywords: Eletriptan HBr, Migraine, Fast dissolving oral films, disintegration time, HPMC, 
Pharmacokinetics. 
Introduction 
Rapidly dissolving or quick dissolving dosage forms have acquired 
great importance in the pharmaceutical industry due to their unique 
properties and advantages 1,2. They undergo disintegration in the 
salivary fluids of the oral cavity within a minute, where they release 
the active pharmaceutical ingredient. The major amount of the 
active pharmaceutical ingredient is swallowed orally with the saliva 
where subsequent absorption takes place in the gastrointestinal 
tract 3, 4. 
The film is an ideal intraoral fast-dissolving drug delivery system, 
which satisfies the unmet needs of the market, is easy to handle 
and administer, maintains a simple and convenient packaging, 
alleviates unpleasant taste, and is straightforward to manufacture. 
Oral fast dissolving film (FDF) is one such novel approach to 
increase consumer acceptance by virtue of rapid dissolution, self 
administration without water or chewing. The need for non-invasive 
delivery systems continues due to patientÊs poor acceptance and 
compliance with existing delivery regimes, limited market size for 
drug companies and drug uses, coupled with high cost of disease 
management 5. 
Orally fast-dissolving film is new drug delivery system for the oral 
delivery of the drugs. It was developed on the basis of technology 
of the transdermal patch. The delivery system consists of a very 
thin oral strip, which is simply placed on the patientÊs tongue or any 
oral mucosal tissue, instantly wet by saliva the film rapidly hydrates 
and adheres onto the site of application. It then rapidly 
disintegrates and dissolves to release the medication for 
oromucosal and intragastric absorption 6.  
When put on the tongue, this film disintegrates instantaneously, 
releasing the drug which dissolves in the saliva. Some drugs are 
absorbed from the mouth, pharynx, and oesophagus as the saliva 
passes down into the stomach. In such cases, the bioavailability of 
the drug is significantly greater than that observed for conventional 
tablets 7. 
Since the drug is directly absorbed into the systemic circulation, 
degradation in the gastrointestinal (GI) tract and first pass effect 
can be avoided 8. These dosage forms possess certain specific 
advantages like no need of water for disintegration, accurate 
dosing, rapid onset of action, ease of transportability, ease of 
handling, pleasant taste and improved patient compliance. 
Migraine is a common, chronic disorder with episodic attacks 9. It 
affects 10-20% of the population during the most productive 
periods of their working lives, women are affected up to four times 
more often than men 10. Eletriptan hydrobromide is a selective 5-
hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist, used in 
the treatment of migraine attacks. The terminal elimination half-life 
of Eletriptan is approximately 4 hours, and is primarily metabolized 
by cytochrome P-450 enzyme CYP3A4 after oral administration. 
Although Eletriptan is well absorbed after oral administration, it 
undergoes first pass metabolism leading to a mean absolute oral 
bioavailability of approximately 50% 11.  
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The available formulation of Eletriptan HBr in market is an 
immediate release tablet. Conventional Eletriptan HBr tablets are 
not suitable where quick onset of action is required. To provide the 
patients with the most convenient mode of administration, there is 
a need to develop rapidly dissolving dosage form, particularly one 
that disintegrates and dissolves/ disperses in saliva and can be 
administered without need of water. Fast dissolving films are useful 
in patients such as paediatric, geriatric, bedridden, or 
developmentally disable who may face difficulty in swallowing 
conventional tablets. So the patients would be benefited from acute 
treatment by using proposed drug delivery system. Thus, a fast 
dissolving film is a unique solid oral dosage form and has valuable 
advantages. The present study is aim to formulate and 
characterize the fast dissolving oral films of Eletriptan HBr for rapid 
onset of action in the management of migraine attack and also to 
improve the bioavailability of the drug.  
Materials and methods 
Materials  
Relpax 20mg film coated tablet was purchased from Pfizer Limited, 
U.K. Eletriptan HBr was received as a gift sample from MSN labs, 
Hyderabad, India. Hydroxy Propyl Methyl Cellulose (HPMC E3, E6 
& E15) was received by Nectar life sciences, Hyderabad, 
Maltodextrin DE6, Xanthan gum and Aspartame was gifted from 
Matrix Labs, Hyderabad. Propylene glycol, Vanillin, Citric acid 
Amaranth purchased from SD FINE CHEM LTD, Mumbai. 
Methanol, Acetonitrile and MilliQ water are of HPLC grade from 
Sigma Aldrich, Mumbai. All other chemicals used were of analytical 
grade. 
Methods 
Preparation of Eletriptan Hydrobromide Films 
Twenty five fast dissolving oral films of Eletriptan hydromide with 
20mg per 4cm2 films were prepared (F1-F25), using solvent 
casting method with different types of polymers and composition 
was shown in table 1, 2 &3. Different grades (HPMC E3, E6 & E15) 
of film forming polymers of Hypromellose and maltodextrin DE6 
were weighed accurately, added to a small amount of water in a 
small beaker, covered with an aluminum foil and soaked foe 24 
hours to ensure complete hydration. Xanthan gum was added the 
next day in small amounts and the solution was stirred on a 
magnetic stirrer at 75rpm for first half an hour and later 50rpm for 
1.5 hours. Then, propylene glycol was added and stirring continued 
for 30min at 50rpm. Eletriptan hydrobromide, Aspartame, citric 
acid, vanillin and amaranth were dissolved in sufficient quantity of 
dimethyl sulfoxide (DMSO) and added to the polymer mixture. This 
film forming solution was stirred well to obtain a homogenous 
solution. The resulting solution was poured into a 9 cm petri dish 
and allowed to dry in hot air oven at 40 ÀC for 24 hours, the dried 
batch carefully removed, cut into desired size12. 
 
Table 1:  Formulation Trials Using HPMC E3 
 Code & Ingredients F1 F2 F3 F4 F5 F6
Eletriptan Hydrobromide (mg) 317.5 317.5 317.5 317.5 317.5 317.5
HPMC E3(mg) 300 325 350 375 400 425
Maltodextrin 250 225 200 175 150 125
Proplylene glycol 100 100 10 100 100 100
Xanthan gum (mg) 10 10 8 8 8 10
Aspartame (mg) 20 20 20 20 20 20
Citric acid  (mg) 10 10 10 10 10 10
Water   (mL) Q.S Q.S Q.S Q.S Q.S Q.S
Vanilla Q.S Q.S Q.S Q.S Q.S Q.S
Amaranth Q.S Q.S Q.S Q.S Q.S Q.S
Dimethyl Sulfoxide Q.S Q.S Q.S Q.S Q.S Q.S
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Table 2:  Formulation Trials Using HPMC E6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3:  Formulation Trials Using HPMC E15 
 
Evaluation of Eletriptan HBR oral films 
Physical characterization of FDOFs 
Physical characterization of FDOFs can be carried out by visual 
inspection for characteristics such as colour, thickness, brittleness, 
peeling ability, transparency, surface smoothness, tack property 
and film forming capacity. 
The prepared films were subjected for in vitro evaluation tests like 
Thickness, Folding Endurance, Surface pH, Morphological 
properties, %Drug content, Tensile strength, Percent elongation, In 
vitro Disintegration time, In vitro Dissolution studies and in vivo 
studies on rabbits. 
Surface pH 
The film to be tested was placed in a Petri dish and was moistened 
with 0.5 ml of distilled water and kept for 30s. The pH was noted 
after bringing the electrode of the pH meter in contact with the 
surface of the formulation and allowing equilibration for 1 min. The 
average of three determinations for each formulation was done 13. 
Weight variation and thickness  
For evaluation of film weight and thickness films were taken and 
weighed individually on a digital balance. The film thickness was 
measured using Digital Vernier caliper (Mitutoyo) at six different 
places and the average value was calculated 14. 
Folding endurance 
The folding endurance is expressed as the number of folds 
(number of times the film is folded at the same place) required to 
break the specimen or to develop visible cracks. This also gives an 
indication of brittleness of the film. A strip of 2.5 cm ï 2.5 cm was 
subjected to folding endurance by folding the patch at the same 
Code & Ingredients F7 F8 F9 F10 F11 F12 F13 F14 F15
Eletriptan 
Hydrobromide(mg) 
317.5 317.5 317.5 317.5 317.5 317.5 317.5 317.5 317.5
HPMC E6(mg) 300 325 350 375 400 425 450 450 475
Maltodextrin 250 250 225 225 200 175 155 100 100
Proplylene glycol 120 120 130 140 140 140 140 140 140
Xanthan gum (mg) 10 10 10 8 8 8 8 8 8
Aspartame (mg) 20 20 20 20 20 20 20 20 20
Citric acid  (mg) 10 10 10 10 10 10 10 10 10
Water   (ml) Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
Vanilla Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
Amaranth Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
Dimethyl sulfoxide Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
Code & Ingredients F16 F17 F18 F19 F20 F21 F22 F23 F24 F25
Eletriptan 
Hydrobromide(mg) 
317.5 317.5 317.5 317.5 317.5 317.5 317.5 317.5 317.5 317.5
HPMC E15           (mg) 300 350 350 375 375 400 400 425 425 450
Maltodextrin 200 200 200 175 175 150 150 150 125 125
Proplylene glycol 120 140 140 140 140 140 140 140 140 140
Xanthan gum (mg) 10 10 10 10 8 8 8 8 8 8
Aspartame (mg) 20 20 20 20 20 20 20 20 20 20
Citric acid  (mg) 10 10 10 10 10 10 10 10 10 10
Water   (ml) Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
Vanilla Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
Amaranth Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
Dimethyl sulfoxide Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
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place repeatedly several times until a visible crack was observed, 
and the values were reported 15. 
%Drug content  
Three films (4 cm2 of each) were transferred in to separate 
graduated flasks containing 100 ml of phosphate buffer pH 6.8 and 
continuously stirred for 2 hrs. The solutions were filtered, suitably 
diluted and analyzed at 221 nm and the drug content was 
calculated 16. 
Percent Elongation  
This mechanical property was evaluated using the Instron universal 
testing instrument (Model F. 4026, Instron Ltd., Japan) with a 5 kg 
load cell. The percentage increase in the length of a film (L2), when 
it is pulled under standard conditions of stress just before the point 
of break is known as percent elongation. The initial length of a film 
is L1, the increase in length is (L2-L1). It is measured in terms of 
percentage. Percent elongation and tensile strength was carried for 
only 4 best formulations. 
                                                               (L2- L1) 
Percent elongation =                                                            X 100 
       L1 X Cross sectional area 
Tensile strength 
Tensile strength is the maximum stress applied to a point at which 
the strip specimen breaks. Film strip of dimension 5 ï 2 cm 2 and 
free from air bubbles or physical imperfections was held between 
two clamps positioned at a distance of 3 cm apart. A cardboard 
was attached on the surface of the clamp via a double sided tape 
to prevent the film from being cut by the grooves of the clamp. 
During measurement, the strips were pulled at the bottom clamp by 
adding weights in pan till the film breaks. The force was measured 
when the films broke.  It is calculated by the applied load at rupture 
divided by the cross‐sectional area of the strip as given in the 
equation below 17. 
                                                                                                 
                                                           Load at Failure 
Tensile strength         =               
                                                   Strip thickness X Strip Width 
In vitro disintegration studies 
Disintegration test was performed to ensure the disintegration of 
the film in phosphate buffer pH 6.8. One film from each formulation 
was introduced into one tube of disintegration apparatus IP. A disc 
was added into the tube. The assembly was suspended in a 
beaker containing phosphate buffer pH 6.8 and the apparatus was 
operated until the film disintegrated 15. 
In vitro dissolution studies 
The phosphate buffer pH 6.8 was taken as the dissolution medium 
to determine the drug release. 
The dissolution profile of quick release films of Almotriptan malate 
was carried out in USP basket type apparatus containing 300 ml of 
the phosphate buffer pH 6.8. The film was placed in the basket, 
maintained at 37 μ 0.5ĈC and the agitation speed was 50 rpm. 
Aliquots (5 ml) of the dissolution medium were withdrawn at 1, 2, 4, 
6, 8 and 10 minutes time intervals and the same amount was 
replaced with the fresh medium. Samples were analyzed 
spectrophotometrically at 221 nm and the cumulative percentage of 
drug release was calculated18. 
Drug excipient compatibility studies 
The drug excipient compatibility studies were carried out by Fourier 
Transmission Infrared Spectroscopy (FTIR) method and Differential 
Scanning Colorimetry (DSC) method. 
Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR spectra for pure drug, physical mixture and optimized 
formulations were recorded using a Fourier transform Infrared 
spectrophotometer. The analysis was carried out in Shimadzu-IR 
Affinity 1 Spectrophotometer. The IR spectrum of the samples was 
prepared using KBr (spectroscopic grade) disks by means of 
hydraulic pellet press at pressure of seven to ten tons.  
Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) studies were carried out 
using DSC 60, having TA60 software, Shimadzu, Japan. The DSC 
thermograms were recorded for pure drug, HPMC E15, 
Maltodextrin, Drug and HPMC mixture and optimized formulation. 
Accurately weighed samples were placed on aluminium plate, 
sealed with aluminium lids and heated at a constant rate of 5ÀC 
/min, over a temperature range of 0 to 250ÀC. 
Stability studies 
The stability study of the optimized fast-dissolving films was carried 
out under different conditions according to ICH guidelines. The film 
was packed in the aluminium foil and stored in a stability chamber 
for stability studies. Accelerated Stability studies were carried out 
at 40 0C / 75 % RH for the best formulations for 6 months. The 
patches were characterized for the drug content and other 
parameters during the stability study period 15. 
Pharmacokinetic study 
Animal Preparation 
Twelve New Zealand white rabbits of either sex were (weighing 2-3 
kg) selected for this study, all the animals were healthy during the 
period of the experiment. Animals were maintained at room 
temperature 250C, RH 45% and 12 h alternate light and dark cycle 
with 100 % fresh air exchange in animal rooms, uninterrupted 
power and water supply and rabbits were fed with standard diet 
and water ad libitum. The protocol of animal study was approved 
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by the institutional animal ethics committee (IAEC NO: 
P35/VCP/IAEC/2015/DBP/AE12/Rabbits).  
In vivo Study design 
The rabbits were fasted overnight before administration of the 
formulations (ODF contain Eletriptan Hydrobromide 20 mg) and 
Innovator (Relpex 20mg). The rabbits were randomly divided into 
two groups each group contains six animals. The group A rabbits 
were anaesthetized with intravenous injection of pentobarbital in a 
dose of 25mg/kg then positioned on table with the lower jaw 
supported in a horizontal position and the ODF was carefully 
placed on the rabbit tongue. The innovator was administered orally 
to group B with equivalent to animal body weight. 
Blood samples for pharmacokinetic analysis were obtained at 
different time intervals 0, 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 
4.00, 5.00, 6.00, 8.00 & 24.00h after doing. Blood samples were 
collected in heparinised tubes and were centrifuged for 10min at 
3,000 rpm at room temperature. 
Preparation of Plasma Samples for HPLC Analysis 
Rabbit plasma (0.5 ml) samples were prepared for chromatography 
by precipitating proteins with 2.5 ml of ice-cold absolute ethanol for 
each 0.5 ml of plasma. After centrifugation the ethanol was 
transferred into a clean tube. The precipitate was re suspended 
with 1 ml of acetonitrile by vortexing for 1 min. After centrifugation 
(5000 ă 6000 rpm for 10 min), the acetonitrile was added to the 
ethanol and the organic mixture was taken to near dryness by a 
steam of nitrogen at room temperature. Samples were 
reconstituted in 200 μ1 of 70 % of acetonitrile and 30% water was 
injected for HPLC analysis. 
For HPLC C18 column (ODS-UG-5, 250 ï4.6 mm, 5μ) and the 
mobile phase consisting of phosphate buffer: Acetonitrile ratio of 
60:40 v/v.  At a flow rate of 0.9 ml/min with UV detection at 221 nm.  
Pharmacokinetic Analysis  
The pharmacokinetic parameters, peak plasma concentrations 
(Cmax) and time to reach peak concentration (tmax) were directly 
obtained from concentration time data. In the present study, AUC0-t 
refers to the AUC from 0 to 24 hrs, which was determined by linear 
trapezoidal rule and AUC0-α refers to the AUC from time at zero 
hours to infinity.  
The AUC0-α was calculated using the formula AUC0-t + [Clast/K] 
where C last is the concentration in μg/ml at the last time point and 
K is the elimination rate constant. 
Various pharmacokinetic parameters like area under the curve 
[AUC], elimination half life (tó). Volume of distribution (Vd), total 
clearance (ClT) and mean residence time for each subject using a 
non compartmental pharmacokinetic programme. The 
pharmacokinetic parameters were performed by a non 
compartmental analysis using Win Nonlin 3.3® pharmacokinetic 
software (Pharsight Mountain View, CA USA). All values are 
expressed as the mean μSD. Statistical analysis was performed 
with Graph Pad InStat software (version 3.00, Graph Pad Software, 
San Diego, CA, USA) using one-way analysis of variance (ANOVA) 
followed by TukeyăKramer multiple comparison test. Difference 
with p<0.05 was considered statistically significant. 
Results and discussion 
Preparation of Eletriptan Hydrobromide films 
Fast dissolving oral films of Eletriptan HBr was prepared with the 
dose of 20mg per 4cm2 film. A total of 25 formulations were 
prepared using three different Hypromellose E3, Hypromellose E6 
and Hypromellose E15 and other polymers, the resulting films were 
shown in Figure 1. 
 
 
 
 
Figure 1: Eletriptan HBr Films 
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Physical Characterization of eletriptan HBr films 
Physical characterization of FDOFs was carried out by visual 
inspection and the following results were observed. 
The films were evenly colored and no migration of color was 
observed. The increased thickness of film is attributed to the 
increase in the amount of HPMC. F1, F2, F4, F5, F6, F9, F10, F11 
and F19 were found to brittle in nature due to insufficient amount of 
plasticizer added to the formulation. F1to F3 and F6 are difficult to 
peel whereas others separated easily. 
F4, F7, F8, F9, F11, F23 were found to be thick. F15, F22 & F24 
were found to be excellent in film forming property, non-tacky, thin, 
flexible and easy to peel. The films obtained from all the 
formulations had smooth surface on either side. Formulations 
prepared using HPMC E3 was not evaluated for physical 
parameters and other tests as they fail to satisfy the preliminary 
characteristics of films due to their poor film forming ability. 
Preliminary Characterization of FDOFÊS 
Physical characterization of FDOFs was carried out by visual 
inspection and the following was observed. 
The films were evenly coloured and no migration of colour was 
observed. All the formulations were checked for film property, tack 
property and brittleness; the results are summarized in Table 4. 
Formulations F10, F13, F16, F17, F18, F20 and F21 found to have 
good film forming property, non-tacky, thin, flexible and easy to 
peel. 
 
Table 4: Preliminary Characterization of FDOFÊS 
Code and properties Film property Tack property Ease of handling 
F1 Poor Non-tacky Brittle, difficult to peel 
F2 Poor Non-tacky Brittle, difficult to peel 
F3 Average Tacky Slightly thick & brittle 
F4 Average Tacky Slightly brittle 
F5 Average Non-tacky Thin, brittle, difficult to peel
F6 Average Tacky Thin, difficult to peel 
F7 Average Tacky Thick, difficult to peel 
F8 Poor Non-tacky Brittle 
F9 Poor Non-tacky Brittle, slightly Opaque 
F10 Good Non-tacky Slightly thick 
F11 Good Non-tacky Slightly thick, opaque 
F12 Good Tacky Thin, tough & flexible 
F13 Good Non-Tacky Thin, tough& flexible 
F14 Poor Non-tacky Brittle 
F15 Poor Tacky Soft, difficult to peel, opaque
F16 Good Non-tacky Easy to peel 
F17 Excellent Non-tacky Thin, flexible and easy to peel
F18 Good Tacky Soft, easy to peel 
F19 Average Non-tacky Slightly thick 
F20 Good Non-tacky Soft, Thick, easy to peel 
F21 Good Non-tacky Soft, thick& easy to peel 
F22 Good Non-tacky Thin, tough& flexible 
F23 Average Non-tacky Thick 
F24 Poor Tacky Very thin soft& difficult to peel
 
Evaluation of fast dissolving oral films of Almotriptan 
malate 
Thickness & Weight variation 
Thickness of all mouth dissolving films was measured with Digital 
Vernier caliper (Mitutoyo). All the mouth dissolving formulations of 
different polymers are show thickness value in the range of 73μ1 to 
91μ1 øm (Table 5). The optimized film (F17) has thickness of 87μ2 
øm. When concentration of polymer increases, thickness and 
weight of the film also increased. The weight variation of the 
formulations was in the range of 50.20μ0.3 to 85.5μ0.5 mg, which 
was acceptable.  
Folding endurance 
Folding endurance gives an indication of brittleness of the film. It 
was shown that as the concentration of polymer and plasticizer 
increases, folding Endurance of mouth dissolving film increases. 
The folding endurance value of the prepared films ranged from 
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40μ1to 115μ3 (Table). The optimized film (F17) has folding 
endurance value of 105μ2, which was desirable. 
Surface pH 
Surface pH of all mouth dissolving films prepared by using different 
polymers was found to be in the range of 6.51 to 6.89 pH (Table ) 
close to the neutral pH, which indicated that films may have less 
potential to irritate the sublingual mucosa, and hence, more 
acceptable by the patients. The optimized film (F17) has surface 
pH value of 6.81.  
%Drug content  
All the fast dissolving oral films were found to contain an almost 
uniform quantity of the drug, as per content uniformity studies 
indicating reproducibility of the technique. Drug content in the films 
was evaluated and the values were found to be between 94.5μ0.46 
to 98.4μ0.5 % (Table) for three different cuts from each film. As per 
the USP requirements, the films found to meet the criteria for 
content uniformity. No significant difference in the drug content 
among the films indicated good content uniformity. 
In vitro disintegration studies 
The disintegrating time of all the formulations was ranges from 
11μ2 to 34μ2sec. The results for all the formulations were 
tabulated in Table 5. The disintegration time of optimized 
formulation (F17) was found to be 11sec, which was very less and 
desirable for quick onset of action. 
 
Table 5: Physical evaluation of fast dissolving oral films of Eletriptan HBr 
Formulatio
n code 
Thickness (øm) Weight 
Variation(mg) 
Folding 
Endurance 
(count) 
Surface pH % Drug content In Vitro 
Disintegration 
time (sec) 
F6 73μ1 50.20μ0.3 40μ1 6.51μ0.04 94.8μ0.24 34μ2 
F7 74μ1 51.22μ0.4 53μ1 6.62μ0.02 95.10μ0.14 30μ2 
F8 72μ1 55.5μ0.1 58μ2 6.79μ0.03 95.45μ0.45 31μ2 
F9 79μ3 54.22μ0.1 61μ1 6.55μ0.04 94.5μ0.7 29μ2 
F10 80μ1 57.64μ0.2 53μ4 6.70μ0.02 94.6μ0.15 29μ2 
F11 74μ1 61.3μ0.2 62μ1 6.85μ0.1 92.54μ0.6 23μ2 
F12 88μ1 63.65μ0.3 64μ2 6.75μ0.05 96.56μ1.2 20μ2 
F13 79μ1 62.1μ0.3 59μ2 6.68μ0.04 92.4μ0.3 18μ2 
F14 88μ0 64.2μ0.12 64μ2 6.93μ0.01 94.3μ1.9 16μ2 
F15 89μ2 85.5μ0.5 100μ2 6.67μ0.02 95.5μ0.8 15μ2 
F16 85μ2 81.5μ0.4 90μ2 6.56μ0.02 95.5μ0.8 14μ2 
F17 87μ2 72.5μ0.6 105μ2 6.81μ0.01 98.4μ0.5 11μ2 
F18 91μ2 62.1μ0.2 95μ2 6.89μ0.01 96.4μ0.5 28μ2 
F19 79μ2 65.69μ0.3 115μ3 6.67μ0.01 94.5μ0.46 26μ2 
F20 87μ0 79.2μ0.5 101μ5 6.81μ0.02 95.7μ1.2 20μ2 
F21 87μ1s 62.3μ0.5 99μ1 6.72μ0.05 95.2μ0.2 18μ2 
F22 87μ0 65.6μ0.4 100μ2 6.78μ0.02 94.5μ0.01 17μ2 
F23 89μ2 73.5μ0.4 104μ2 6.74μ0.03 94.5μ0.6 14μ2 
F24 85μ2 76.2μ0.5 115μ3 6.68μ0.01 95.56μ0.3 15μ2 
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Figure 2: In vitro Disintegration Time of HPMC E6 formulations (F6- F15) 
 
 
 
Figure 3: In vitro Disintegration Time of HPMC E15 formulations 
 
Tensile Strength and Percent Elongation 
Tensile strength was performed for selected formulations that are 
more similar to the optimized formulation. 
 
Table 6: Tensile Strength and Percent Elongation 
Formulation 
Code 
Tensile Strength 
(g/cm2) 
Percent elongation 
(%) 
F16 9.2 8.2
F17 10.6 9.4
F23 9.7 8.5
F24 10.4 9.0
In vitro Dissolution Studies   
In-vitro drug dissolution study of eletriptan HBr oral 
dissolving films 
The cumulative % drug release for the formulations F7 to F15 and 
F16 to F24 are tabulated in Table 7 and 8 and Figure 4 and 5 
respectively. The optimized formulation (F17) showed highest 
percent of drug release 98.5 by the end of 10 min when compared 
with other formulations. 
The cumulative % drug release studies of optimized formulation 
F17 was compared with the marketed RELPAX (20mg) 
conventional tablet and the drug release of F17 and innovator was 
found to be 98.5 and 79.4 respectively after 10min, which shown in 
Table 9 and Figure 6. 
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Table 7: Cumulative Percentage Drug Release for HPMC E6 
 
 
Table 8: Cumulative Percentage Drug Release for HPMC E15 
 
 
 
Figure 4: Cumulative Percentage Drug Release for HPMC E6 (Formulations F7-F15) 
 
 
 
Figure 5: Cumulative Percentage Drug Release for HPMC E15 (formulations F16-24) 
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 F7 F8 F9 F10 F11 F12 F13 F14 F15
0 0 0 0 0 0 0 0 0 0
1 35.45+1.4 42.04+1.2 32.2+3.01 38.7+1.12 42.5+2.045 48.2+2.55 44+1.21 32.45+1.6 29.7+1.4
2 50.11+1.11 53.48+2.54 51.2+1.35 45.7+1.58 57.3+2.21 55.1+3.08 52+3.56 37.25+1.22 55.3+2.55
4 55.25+1.23 64.82+2.64 75.2+2.62 64.8+2.09 66.5+1.25 69.2+2.56 73+2.2 44.31+2.75 68.5+2.72
6 68.47+2.65 75.65+3.08 79+3.55 70.2+2.46 72.5+1.88 74.1+1.59 80.8+1.81 61.36+2.68 70.7+3.05
8 84.3+2.02 86.6+2.64 84.2+2.88 74.5+2.55 84.6+0.96 88.8+1.8 85+2.51 75.11+2.03 80.2+2.65
10 88.05+1.85 90.8+1.86 87.2+1.75 82.2+2.71 89.9+1.48 92+2.81 91.92+1.3 87.54+1.86 84.6+1.89
Time 
  
Formulation code
F16 F17 F18 F19 F20 F21 F22 F23 F24
0 0 0 0 0 0 0 0 0 0
1 42.5+3.01 42.8+1.41 36.6+2.045 27.35+2.55 22.12+1.21 25.21μ1.4 23.12μ2.4 22.16μ2.6 27.21μ3.2
2 51.5+1.25 63.5+1.58 42.23+2.21 35.81+1.62 39.52+1.4 35.42μ2.1 36.42μ2.4 38.21μ1.23 36.72μ2.39
4 72.3+2.09 79.9+1.25 53.77+2.66 53.55+2.27 55.87+1.7 48.27μ4.7 49.23μ5.2 52.23μ3.2 57.28μ2.23
6 83.4+3.55 82+2.36 62.47+1.88 70.8+3.21 72.55+1.5 63.45μ2.6 55.02μ5.2 67.28μ5.2 67.56μ1.7
8 87.9+2.88 90+2.55 71.1+0.96 82.04+1.8 85.5+2.04 75.02μ2.23 60.25μ4.25 79.23μ4.2 81.49μ2.3
10 93.7+1.75 98.5+2.71 88.9+1.48 92.35+1.18 89.6+3.11 82.13μ4.23 85.23μ2.5 88.23μ3.2 90.26μ2.6
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Comparison of optimized formulation with innovator 
product 
From the above studies F17 was found optimum for the formulation 
of Eletriptan hydrobromide FDOFs. Thus cumulative drug release 
studies of F17 formulation was compared with the marketed 
RELPAX-20mg film coated tablets. 
 
Table 9: Comparison of Cumulative drug release of F17 with innovator product of RELPAX-20mg tablets  
TIME (Min) 0 1 2 4 6 8 10
F17 0 42.8+1.41 63.5+1.58 79.9+1.25 82+2.36 90+2.55 98.5+2.71
RELPAX-Film coated 
tablets (20mg) 
0 22+2.52 34+1.74 48+3.5 59+2.2 72+2.5            79.4+1.2
 
 
 
Figure 6: Comparison of Cumulative drug release of F17 with innovator product of RELPAX-20mg tablets. Drug excipient interactions 
studies by FTIR   Spectroscopy: 
 
Figure 7: FTIR spectra of Eletriptan HBr pure drug 
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Figure 8: FTIR spectra of xanthan gum 
               
 
Figure 9: FTIR spectra of optimized formulation (F17) 
 
The FTIR spectra of pure Eletriptan HBr (Figure 7) displayed band 
at 1643 cm-1 due to heterocyclic c=c bond, at 1453 cm-1  due to C-
H  bending, at 1333 cm-1  due to S=O. The spectra also showed 
bands at 1586 cm-1 due to N-H bending, Xanthan gum exhibited 
characteristic bands at 2898 cm-1 due to C-H stretching, at 1645 
cm-1 due to Hetero cyclic C=C, at 1452cm-1 due to C-H bending 
(Figure 8), at  
The FTIR spectrum of optimized formulation (Figure 9) exhibited 
characteristic bands consistent with the molecular structure of  
 
Eletriptan Hydrobromide such as bands at 2921 cm-1 due to C-H 
stretch, at 1773 cm-1 due to C=O stretching, at  3427cm-1 due to N-
CH3, at 1389cm-1 due to S=O, at 1588 cm-1  due to C-H bending. 
The Eletriptan HBr film formulation exhibited peaks at 2901 cm-1  
due to C-H stretching, at 3429 cm-1  due to N-CH3. Thus, the 
presence of characteristic absorption bands of Eletriptan 
Hydrobromide and the film containing Eletriptan Hydrobromide 
suggest that there is no interaction takes place between the drug 
and excipients used in the formulation. 
Drug excipient compatibility studies by DSC 
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Figure 10: DSC thermogram of Eletriptan pure drug (A) and 
optimized formulatin F17  (B) 
Interpretation of DSC Data 
DSC thermograms revealed that there is no considerable change 
observed in melting endotherm of Eletriptan HBr pure drug (169) 
and  optimized formulation F17 (170) (Figure 10). It indicates that 
there is no interaction takes place between drug and other 
excipients used in the formulation. 
Stability Studies for optimized formulation (F17) 
Stability studies were conducted for optimized formulation (F17) for 
the period of 6 months according to ICH guidelines. Different 
parameters like disintegration time, % drug content, transparency 
and in vitro %drug release was evaluated. From these results it 
was concluded that, optimized formulation F17 is stable and 
retained their original properties with minor differences which 
depicted in Table 10.  
 
Table 10: Physico-chemical characteristics of optimized formulation (F17) stored at 40 μ2ÀC /75 μ5%RH 
Retest time for 
optimized 
formulation (F17) 
Disintegrating Time 
(sec) 
Percent Drug 
Content  
In-vitro drug 
release profile (%) 
Transparency 
0 days 11+ 2 98.4+0.22 98.5+4.70 Transparent 
1 month 12+ 6 97.86+0.14 97.8+3.61 Transparent 
3 months 12+ 9 97.06+0.12 97.2+2.71 Transparent 
6 months 13+ 5 97.54+0.26 96.5+6.72 Transparent 
Pharmacokinetic study: 
 
 
 
Figure 11: Plasma concentrations at different time intervals for Eletriptan Hydrobromide optimized formulation film F17 and innovator (Relpax 
20mg) 
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Table 11: Comparison of pharmacokinetic parameters of Eletriptan Hydrobromide between the optimized formulation film F17 and innovator 
(Relpax 20mg) in Rabbits (mean μ SD, n = 6). 
Parameters Optimized formulation  F17 Innovator (RELPAX 20mg) 
C max (øg/ml) 0.455μ0.1 0.418μ0.2 
AUC 0-t (øg hr/ml) 3.36μ56.44 3.29μ44.26 
AUC 0-inf (øg hr/ml) 3.74μ28.14 3.54μ38.12 
T max (hr) 0.50μ1.23 1.0μ2.24 
t 1/2 (hr) 1.253 μ 0.519 2.364 μ 0.01
K el (hr -1) 1.336 μ 0.11 1.196 μ 0.33 
 
Bioavailability parameters 
Drug release from Eletriptan Hydrobromide optimized formulation 
was almost similar to that from commercial formulation which was 
selected. Mean plasma concentration profiles of Eletriptan 
Hydrobromide optimized formulation and commercial formulation 
are presented in Figure 11. Both the formulations exhibited as 
immediate release in vivo. As compared to the innovator prepared 
film was showed immediate release. All the pharmacokinetics 
parameters displayed in Table 11. Mean time to reach peak drug 
concentration (Tmax) was 0.50μ1.23h and 1.0μ2.24h for the 
optimized and commercial formulations, respectively, while mean 
maximum drug concentration (Cmax) was 0.455μ0.2øg/ml and 
0.418μ0.1øg/ml respectively. 
Summary and conclusion 
In the present investigation, twenty five formulations of Eletriptan 
HBr fast dissolving oral films were prepared with HPMC E3, E6 & 
E15, maltodextrin, xanthan gum, propylene glycol. Formulations 
with HPMC E3 were not evaluated for physical parameters due to 
their poor film forming ability, tack property and ease of handling or 
peeling. The bitter taste of the drug was masked by Aspartame and 
Vanilla flavour. Formulations with HPMC E6 and E15 were 
evaluated for their physical characteristics, thickness, folding 
endurance, tensile strength, disintegration time, drug content 
uniformity and drug release characteristics and found to be within 
the limits. Among the prepared formulations F17 showed minimum 
disintegration time 11 sec, maximum drug was released i.e. 98.5% 
of drug within 10 min when compared to the other formulations and 
finalized as optimized formulation. DSC and FTIR data revealed 
that no interactions takes place between the drug and polymers 
used in the optimized formulation. The in vitro dissolution profiles of 
marketed product (RELPAX-20mg) and optimized formulation was 
compared and found to be the drug released was 79.4% within 
10min from the marketed product, whereas from optimized 
formulation (F17) the drug release was 98.5% within 10min. 
Therefore it can be a good alternative to conventional Eletriptan 
HBr tablets for immediate action. In vitro and in vivo evaluation of 
the Eletriptan HBr fast dissolving films confirmed their potential as 
an innovative dosage form to improve delivery and quick onset of 
action of Eletriptan HBr. Therefore, the oral fast dissolving film is 
considered to be potentially useful for the treatment of migraine 
disease where the quick onset of action is desired, also improved 
patient compliance. 
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